(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00B4Q5ZN47

Sleep Disorder, Epilepsy, Oncology

Pharmaceuticals
Market Cap in USD: 9,738m

IPO / Inception: 2007-06-01
12m vs SPY: 15.8%

EPS (Earnings per Share)

EPS CAGR: 19.18%
EPS Trend: -31.0%

Last SUE: 0.91
Qual. Beats: 1

Revenue

Rev. CAGR: 6.26%
Rev. Trend: 70.7%

Last SUE: 0.49
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	34.9%
Value at Risk 5%th	53.5%
Relative Tail Risk	-6.85%

Reward TTM
Sharpe Ratio	0.91
Alpha	22.44
CAGR/Max DD	0.08

Character TTM
Hurst Exponent	0.337
Beta	0.757
Beta Downside	1.107

Drawdowns 3y
Max DD	38.02%
Mean DD	20.81%
Median DD	21.62%

Description: JAZZ Jazz Pharmaceuticals January 09, 2026

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a Dublin-based, globally-focused biopharma that markets a portfolio of specialty medicines across neurology, oncology, and rare-disease indications. Its core commercial products include Xywav and Xyrem for narcolepsy-related sleep disorders, Epidiolex for refractory epilepsies (LGS, DS, TSC), and a suite of oncology agents such as Zepzelca (small-cell lung cancer) and Vyxeos (therapy-related acute myeloid leukemia). The company also maintains a robust pipeline, with late-stage candidates like Zanidatamab (HER2-positive gastro-esophageal cancers) and early-stage programs targeting Parkinson’s tremor, PTSD, and pan-RAF inhibition.

Key financial metrics (FY 2023) show total revenue of approximately $2.2 billion, driven primarily by strong growth in the CNS franchise (+22% YoY) and expanding oncology sales. Jazz reported an adjusted EBITDA margin of roughly 28% and a diluted EPS of $2.48, reflecting its high-margin specialty focus. The stock trades at a forward P/E near 15×, modestly below the GICS Pharmaceuticals median, while the company’s cash-flow conversion exceeds 80%, providing runway for continued R&D investment.

Sector-wide drivers that influence Jazz’s outlook include an aging population increasing demand for neurologic and oncology therapies, persistent pricing pressure from payer reforms in the U.S., and the broader industry shift toward biologics and targeted small-molecule combos. Jazz’s strategic collaborations (e.g., with Sumitomo Pharma and Zymeworks) diversify risk and accelerate access to novel modalities, positioning it to capture incremental market share as new indications receive regulatory approval.

For a deeper quantitative view, you may want to explore Jazz’s metrics on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (-368.5m TTM) > 0 and > 6% of Revenue (6% = 249.5m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA 2.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 35.64% (prev 84.16%; Δ -48.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.39b > Net Income -368.5m (YES >=105%, WARN >=100%)

Net Debt (4.19b) to EBITDA (257.5m) ratio: 16.28 <= 3.0 (WARN <= 3.5)

Current Ratio 1.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (61.6m) change vs 12m ago -2.48% (target <= -2.0% for YES)

Gross Margin 85.39% (prev 85.58%; Δ -0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 35.22% (prev 32.58%; Δ 2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.13 (EBITDA TTM 257.5m / Interest Expense TTM 200.9m) >= 6 (WARN >= 3)

Altman Z'' 0.72

(A) 0.13 = (Total Current Assets 3.76b - Total Current Liabilities 2.27b) / Total Assets 11.36b

(B) 0.04 = Retained Earnings (Balance) 442.7m / Total Assets 11.36b

(D) -0.02 = Book Value of Equity -126.6m / Total Liabilities 7.40b

Total Rating: 0.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 52.10

1. Piotroski 5.0pt

2. FCF Yield 10.19%

3. FCF Margin 32.14%

4. Debt/Equity 1.37

5. Debt/Ebitda 16.28

6. ROIC - WACC (= -9.39)%

7. RoE -9.25%

8. Rev. Trend 70.71%

9. EPS Trend -30.97%

What is the price of JAZZ shares?

As of January 16, 2026, the stock is trading at USD 170.81 with a total of 1,790,465 shares traded.
Over the past week, the price has changed by +0.85%, over one month by +0.76%, over three months by +27.65% and over the past year by +38.92%.

Is JAZZ a buy, sell or hold?

Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.

Strong Buy: 10
Buy: 6
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the JAZZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	214.1	25.3%
Analysts Target Price	214.1	25.3%
ValueRay Target Price	191.4	12%

JAZZ Fundamental Data Overview January 10, 2026

P/E Forward = 8.3612
P/S = 2.342
P/B = 2.5996
P/EG = 3.9828
Revenue TTM = 4.16b USD
EBIT TTM = -428.0m USD
EBITDA TTM = 257.5m USD
Long Term Debt = 4.33b USD (from longTermDebt, last quarter)
Short Term Debt = 1.04b USD (from shortTermDebt, last quarter)
Debt = 5.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.19b USD (from netDebt column, last quarter)
Enterprise Value = 13.12b USD (9.74b + Debt 5.43b - CCE 2.05b)
Interest Coverage Ratio = -2.13 (Ebit TTM -428.0m / Interest Expense TTM 200.9m)
EV/FCF = 9.82x (Enterprise Value 13.12b / FCF TTM 1.34b)
FCF Yield = 10.19% (FCF TTM 1.34b / Enterprise Value 13.12b)
FCF Margin = 32.14% (FCF TTM 1.34b / Revenue TTM 4.16b)
Net Margin = -8.86% (Net Income TTM -368.5m / Revenue TTM 4.16b)
Gross Margin = 85.39% ((Revenue TTM 4.16b - Cost of Revenue TTM 607.4m) / Revenue TTM)
Gross Margin QoQ = 77.11% (prev 88.88%)
Tobins Q-Ratio = 1.16 (Enterprise Value 13.12b / Total Assets 11.36b)
Interest Expense / Debt = 0.89% (Interest Expense 48.6m / Debt 5.43b)
Taxrate = 21.0% (US default 21%)
NOPAT = -338.1m (EBIT -428.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.65 (Total Current Assets 3.76b / Total Current Liabilities 2.27b)
Debt / Equity = 1.37 (Debt 5.43b / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = 16.28 (Net Debt 4.19b / EBITDA 257.5m)
Debt / FCF = 3.14 (Net Debt 4.19b / FCF TTM 1.34b)
Total Stockholder Equity = 3.98b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.12% (Net Income -368.5m / Total Assets 11.36b)
RoE = -9.25% (Net Income TTM -368.5m / Total Stockholder Equity 3.98b)
RoCE = -5.15% (EBIT -428.0m / Capital Employed (Equity 3.98b + L.T.Debt 4.33b))
RoIC = -3.55% (negative operating profit) (NOPAT -338.1m / Invested Capital 9.53b)
WACC = 5.85% (E(9.74b)/V(15.17b) * Re(8.71%) + D(5.43b)/V(15.17b) * Rd(0.89%) * (1-Tc(0.21)))
Discount Rate = 8.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -5.97%
[DCF Debug] Terminal Value 88.07% ; FCFF base≈1.25b ; Y1≈1.49b ; Y5≈2.30b
Fair Price DCF = 1040 (EV 67.39b - Net Debt 4.19b = Equity 63.20b / Shares 60.8m; r=5.90% [WACC]; 5y FCF grow 19.69% → 2.90% )
EPS Correlation: -30.97 | EPS CAGR: 19.18% | SUE: 0.91 | # QB: 1
Revenue Correlation: 70.71 | Revenue CAGR: 6.26% | SUE: 0.49 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.97 | Chg30d=-0.469 | Revisions Net=-2 | Analysts=8
EPS next Year (2026-12-31): EPS=22.04 | Chg30d=-0.674 | Revisions Net=-2 | Growth EPS=+172.5% | Growth Revenue=+6.4%

Additional Sources for JAZZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle